Combining Real-World and Randomized Control Trial Data Using Data-Adaptive Weighting via the On-Trial Score
暂无分享,去创建一个
[1] Michael Branson,et al. A note on the power prior , 2009, Statistics in medicine.
[2] S. Shariat,et al. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. , 2019, Clinical genitourinary cancer.
[3] L. Egevad,et al. Prognostic value of the Gleason score in prostate cancer , 2002, BJU international.
[4] Keying Ye,et al. Normalized Power Prior Bayesian Analysis , 2022, 2204.05615.
[5] Heng Li,et al. Propensity score-integrated composite likelihood approach for incorporating real-world evidence in single-arm clinical studies , 2019, Journal of biopharmaceutical statistics.
[6] Margaret Gamalo-Siebers,et al. Propensity‐score‐based priors for Bayesian augmented control design , 2018, Pharmaceutical statistics.
[7] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[8] Lorenzo Trippa,et al. Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data , 2019, Clinical Cancer Research.
[9] J. Rassen,et al. Effects of expanding the look‐back period to all available data in the assessment of covariates , 2017, Pharmacoepidemiology and drug safety.
[10] N. Dreyer,et al. Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control arms , 2020, Pharmacoepidemiology and drug safety.
[11] Frank Bretz,et al. Beyond Randomized Clinical Trials: Use of External Controls , 2019, Clinical pharmacology and therapeutics.
[12] S. Griffith,et al. An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database , 2019, Pharmacoepidemiology and drug safety.
[13] J. Ibrahim,et al. Power prior distributions for regression models , 2000 .
[14] S. Ramsey,et al. Using electronic health record data to identify comparator populations for comparative effectiveness research , 2020, Journal of medical economics.
[15] K. Tsui,et al. Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis , 2017, OncoTargets and therapy.
[16] S J Pocock,et al. The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.
[17] Joseph G. Ibrahim,et al. Power prior distributions for generalized linear models , 2000 .
[18] G. Scagliotti,et al. Metastatic castration-resistant prostate cancer: time for innovation. , 2015, Future oncology.
[19] Rajendra Prasad,et al. Alkaline Phosphatase: An Overview , 2013, Indian Journal of Clinical Biochemistry.
[20] H. Hansen,et al. Performance status assessment in cancer patients. An inter-observer variability study. , 1993, British Journal of Cancer.
[21] Jerome P. Reiter,et al. A comparison of two methods of estimating propensity scores after multiple imputation , 2016, Statistical methods in medical research.